Simvastatin in Critically Ill Patients with Covid-19
This study evaluated the effectiveness of simvastatin (a cholesterol-lowering medication) in treating critically ill COVID-19 patients. The trial involved 2684 patients and aimed to determine if simvastatin could increase the number of days free from respiratory and cardiovascular support. The results showed that simvastatin did not meet the criteria for superiority compared to the control group, although it showed some promise in improving patient outcomes. However, simvastatin was associated with more frequent serious adverse events.